NDAORALTABLET
Approved
May 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
CORZIDE (bendroflumethiazide; nadolol) by Pfizer is clinical pharmacology nadolol nadolol is a nonselective beta-adrenergic receptor blocking agent. Approved for hypertension, to lower blood pressure, heart failure. First approved in 1983.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CORZIDE is a fixed-dose combination of bendroflumethiazide (thiazide diuretic) and nadolol (nonselective beta-blocker) indicated for hypertension management. Nadolol reduces heart rate, cardiac output, and blood pressure by blocking beta-adrenergic receptors, while bendroflumethiazide enhances sodium and water excretion. The combination provides synergistic antihypertensive effects suitable for long-term blood pressure control.
LOE Approaching
As LOE approaches, the brand team will focus on lifecycle extension, generic containment, and managed transition rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Nadolol Nadolol is a nonselective beta-adrenergic receptor blocking agent. Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac output at rest and on exercise, (2) reduction of systolic and diastolic blood…
Worked on CORZIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.